Cargando…

Designs and Characterization of Subunit Ebola GP Vaccine Candidates: Implications for Immunogenicity

The humoral responses of Ebola virus (EBOV) survivors mainly target the surface glycoprotein GP, and anti-GP neutralizing antibodies have been associated with protection against EBOV infection. In order to elicit protective neutralizing antibodies through vaccination a native-like conformation of th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Agnolon, Valentina, Kiseljak, Divor, Wurm, Maria J., Wurm, Florian M., Foissard, Charlotte, Gallais, Fabrice, Wehrle, Sarah, Muñoz-Fontela, César, Bellanger, Laurent, Correia, Bruno Emanuel, Corradin, Giampietro, Spertini, François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672190/ https://www.ncbi.nlm.nih.gov/pubmed/33250896 http://dx.doi.org/10.3389/fimmu.2020.586595

Ejemplares similares

Large-scale mapping of the Ebola NP and GP proteins reveals multiple immunoprevalent and conserved CD4 T-cell epitopes
por: Gallais, Yann, et al.
Publicado: (2020)

Influence of glutamine on transient and stable recombinant protein production in CHO and HEK-293 cells
por: Rajendra, Yashas, et al.
Publicado: (2011)

The use of filler DNA for improved transfection and reduced DNA needs in transient gene expression with CHO and HEK cells
por: Kiseljak, Divor, et al.
Publicado: (2011)

Polyethyleneimine-based transient gene expression processes for suspension-adapted HEK-293E and CHO-DG44 cells
por: Hacker, David L., et al.
Publicado: (2013)

P. falciparum and P. vivax Orthologous Coiled-Coil Candidates for a Potential Cross-Protective Vaccine
por: Ayadi, Imen, et al.
Publicado: (2020)

Boosted Pro-Inflammatory Activity in Human PBMCs by Lipopolysaccharide and SARS-CoV-2 Spike Protein Is Regulated by α-1 Antitrypsin †
por: Tumpara, Srinu, et al.
Publicado: (2021)

The Synthetic Plasmodium falciparum Circumsporozoite Peptide PfCS102 as a Malaria Vaccine Candidate: A Randomized Controlled Phase I Trial
por: Audran, Régine, et al.
Publicado: (2009)

Epitope Mapping and Fine Specificity of Human T and B Cell Responses for Novel Candidate Blood-Stage Malaria Vaccine P27A
por: Geiger, Kristina M., et al.
Publicado: (2020)

Structures of Ebola Virus GP and sGP in Complex with Therapeutic Antibodies
por: Pallesen, Jesper, et al.
Publicado: (2016)

Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo
por: Hoff, Nicole A., et al.
Publicado: (2022)

Intradermal immunization by Ebola virus GP subunit vaccines using microneedle patches protects mice against lethal EBOV challenge
por: Liu, Ying, et al.
Publicado: (2018)

Ebola Virus Disease in Humans: Pathophysiology and Immunity
por: Muñoz-Fontela, César, et al.
Publicado: (2017)

A Malaria Vaccine That Elicits in Humans Antibodies Able to Kill Plasmodium falciparum
por: Druilhe, Pierre, et al.
Publicado: (2005)

Author Correction: Intradermal immunization by Ebola virus GP subunit vaccines using microneedle patches protects mice against lethal EBOV challenge
por: Liu, Ying, et al.
Publicado: (2023)

Ebola GP-Specific Monoclonal Antibodies Protect Mice and Guinea Pigs from Lethal Ebola Virus Infection
por: Qiu, Xiangguo, et al.
Publicado: (2012)

Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial
por: Agnandji, Selidji T., et al.
Publicado: (2017)

Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides
por: Pellaton, Céline, et al.
Publicado: (2013)

The role of the charged residues of the GP2 helical regions in Ebola entry
por: Jiang, Haiqing, et al.
Publicado: (2009)

Ebola sGP—The first viral glycoprotein shown to be C-mannosylated
por: Falzarano, Darryl, et al.
Publicado: (2007)

28. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO™) in Participants by Age, Sex, and Baseline GP-ELISA Titer: A Post Hoc Analysis of Three Phase 2/3 Trials
por: Simon, Jakub, et al.
Publicado: (2020)

Malaria Vaccines: Progressing on a Bumpy Road
por: Corradin, Giampietro, et al.
Publicado: (2014)

Priming of CD8(+) T Cell Responses to Liver Stage Malaria Parasite Antigens
por: Corradin, Giampietro, et al.
Publicado: (2014)

Immunogenicity and efficacy of recombinant subunit SARS-CoV-2 vaccine candidate in the Syrian hamster model
por: Shanmugaraj, Balamurugan, et al.
Publicado: (2022)

Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters
por: Azizi, Ali, et al.
Publicado: (2006)

Comprehensive Functional Analysis of N-Linked Glycans on Ebola Virus GP1
por: Lennemann, Nicholas J., et al.
Publicado: (2014)

Shed GP of Ebola Virus Triggers Immune Activation and Increased Vascular Permeability
por: Escudero-Pérez, Beatriz, et al.
Publicado: (2014)

Dermal Delivery of a SARS-CoV-2 Subunit Vaccine Induces Immunogenicity against Variants of Concern
por: McMillan, Christopher L. D., et al.
Publicado: (2022)

Shotgun proteomics analysis of SARS-CoV-2-infected cells and how it can optimize whole viral particle antigen production for vaccines
por: Grenga, Lucia, et al.
Publicado: (2020)

Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2013)

2838. Safety and Immunogenicity of a gp120-CD4 Chimeric Subunit Vaccine: A Phase 1a Randomized Controlled Trial
por: Chua, Joel V, et al.
Publicado: (2019)

Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial
por: Chua, Joel V., et al.
Publicado: (2021)

Correction: Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2014)

Retraction: Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector
Publicado: (2020)

Development of Designed Site-Directed Pseudopeptide-Peptido-Mimetic Immunogens as Novel Minimal Subunit-Vaccine Candidates for Malaria
por: Lozano, José Manuel, et al.
Publicado: (2010)

First-In-Human Trials of GamTBvac, a Recombinant Subunit Tuberculosis Vaccine Candidate: Safety and Immunogenicity Assessment
por: Vasina, Daria V., et al.
Publicado: (2019)

RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates
por: Pan, Xiaoyan, et al.
Publicado: (2021)

Zoonotic risk factors associated with seroprevalence of Ebola virus GP antibodies in the absence of diagnosed Ebola virus disease in the Democratic Republic of Congo
por: Bratcher, Anna, et al.
Publicado: (2021)

Identification of Ebola Virus Inhibitors Targeting GP2 Using Principles of Molecular Mimicry
por: Singleton, Courtney D., et al.
Publicado: (2019)

Ebola Virus GP Activates Endothelial Cells via Host Cytoskeletal Signaling Factors
por: Moni, Benedicte Mpia, et al.
Publicado: (2022)

Shortlisting SARS‐CoV‐2 Peptides for Targeted Studies from Experimental Data‐Dependent Acquisition Tandem Mass Spectrometry Data
por: Gouveia, Duarte, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tu1djdb0hol3i34uljho4dik92